AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
188.34
+1.66 (+0.89%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close186.68
Open188.07
Bid187.80 x 800
Ask188.31 x 1400
Day's Range185.99 - 189.10
52 Week Range163.31 - 210.19
Volume3,314,607
Avg. Volume3,176,850
Market Cap117.2B
Beta (3Y Monthly)0.97
PE Ratio (TTM)14.92
EPS (TTM)12.62
Earnings DateApr 22, 2019 - Apr 26, 2019
Forward Dividend & Yield5.80 (3.11%)
Ex-Dividend Date2019-02-14
1y Target Est204.38
Trade prices are not sourced from all markets
  • Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
    Zacks16 hours ago

    Merck Gets Priority Review for Keytruda Combo in Kidney Cancer

    Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.

  • TheStreet.comyesterday

    Behind the Cutting Edge Technology: The History of Amgen

    This biotechnology company got it's start California. Watch 'Behind the Label' TheStreet's new video series to learn more.

  • Is Amgen a Buy?
    Motley Foolyesterday

    Is Amgen a Buy?

    There's good news and there's bad news for this big biotech.

  • Moody's3 days ago

    Amgen Inc. -- Moody's announces completion of a periodic review of ratings of Amgen Inc.

    Announcement: Moody's announces completion of a periodic review of ratings of Amgen Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Amgen Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • This Is One Company That Could Break Up Bristol-Celgene Deal
    Investor's Business Daily3 days ago

    This Is One Company That Could Break Up Bristol-Celgene Deal

    Bristol-Myers Squibb could still be in play, an analyst said Friday, suggesting Johnson and Johnson, Pfizer or Amgen could make a bid. That would break up Bristol's takeover of Celgene.

  • The Wall Street Journal4 days ago

    [$$] WSJ Tax Guide 2019: The Drug Industry

    The tax overhaul has given pharmaceutical companies that generate hefty sales outside the U.S. the chance to bring cash home at a preferential rate. Multinational drug companies were big beneficiaries from the tax overhaul because they generate a good chunk of their sales outside the U.S. and had been keeping billions of dollars overseas to avoid having to pay U.S. taxes on the sums. With taxes falling, drug-company profits have soared, according to a Wall Street Journal review of securities filings for the first nine months of 2018.

  • Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
    Zacks4 days ago

    Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

    Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

  • Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down
    Zacks5 days ago

    Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down

    Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.

  • Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report
    Zacks5 days ago

    Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report

    Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.

  • Moat Index: Dramatic Sector Allocation Shift in 2018
    Market Realist5 days ago

    Moat Index: Dramatic Sector Allocation Shift in 2018

    What Did 2018 Bring for Moat Stocks?(Continued from Prior Part)VanEck New Year, New Positioning The U.S. Moat Index is reviewed quarterly to ensure the Index is allocated to companies that Morningstar believes possess a sustainable competitive

  • Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer
    Zacks7 days ago

    Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer

    Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

  • Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%
    Zacks7 days ago

    Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%

    Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.

  • AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
    Zacks7 days ago

    AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma

    AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.

  • Barrons.com7 days ago

    Regeneron’s 60% Price Cut Shows Heat Is Still on Drug Companies

    A growing effort to push back on price increases is affecting pharmaceutical companies. Regeneron and Sanofi are the latest to announce a cut, for the cholesterol drug Praluent.

  • Reuters8 days ago

    Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

    Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug. The new list price for Praluent will be $5,850 (£4,533) a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.

  • Reuters8 days ago

    Sanofi and Regeneron cut list price of cholesterol drug by 60 pct

    Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug. The new list price for Praluent will be $5,850 a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.

  • 2 Days Left To Cash In On Amgen Inc. (NASDAQ:AMGN) Dividend
    Simply Wall St.8 days ago

    2 Days Left To Cash In On Amgen Inc. (NASDAQ:AMGN) Dividend

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors who want to cash in onRead More...

  • Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View
    Zacks11 days ago

    Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View

    Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGNView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $16.03 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. AMGN credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Investing.com12 days ago

    Amgen Falls 3%

    Investing.com - Amgen (NASDAQ:AMGN) fell by 3.09% to trade at $184.86 by 10:51 (15:51 GMT) on Thursday on the NASDAQ exchange.

  • Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down
    Zacks13 days ago

    Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down

    Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.

  • Roche Submits sBLA to FDA for Label Expansion of Kadcyla
    Zacks14 days ago

    Roche Submits sBLA to FDA for Label Expansion of Kadcyla

    Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.

  • Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy
    Zacks15 days ago

    Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy

    Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.

  • Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod
    Zacks15 days ago

    Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod

    Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets recommendation from CHMP of the EMA.

  • Benzinga16 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

    The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN ), Novartis AG (NYSE: NVS ) and Illumina, Inc. (NASDAQ: ILMN )  reporting either disappointing results or ...